Ucardi was founded in 2065438+February 2005. At present, You Caldi has not only completed the establishment of closed loop of scientific research-transformation-clinical technology products, but also built three complete GMP production and production chains for the whole CAR-T production chain.
The production basis of quality management detection system includes the production of clinical plasmids, lentivirus vectors and CAR-T cells. Under this production management system, more than 1000 CAR-T cases have been completed with hematology departments of many well-known large-scale tertiary hospitals in China.
Real-world clinical research and sympathetic rescue treatment have achieved the expected results consistent with international clinical trial reports, but they have outstanding advantages in safety. In 20 19, the relevant personnel of the European Patent Office published a CAR-T patent application in Nature Biotechnology, and approved the analysis. Caldi ranks fourth in the world.
At the same time, you Caldi won the honor of "China Cell Therapy Enterprise Rapid Growth Award", "20 19 Future Medical Care 100 Top List of China Innovative Drugs 100 Top List" and "China Innovative Pharmaceutical Enterprises 100 Top List in 2020". Reach a strategic cooperation and invest in the construction of gene cell therapy center in Boao, Hainan.
For details of the conditions for the acquisition of control rights by Xinhua International Huayao Holdings, please refer to the Acquisition Agreement for Control Rights of Controlling Shareholders and Actual Controllers and the Prompt Announcement for Controlling Shareholders and Actual Controllers and the Supplementary Agreement on Signing the Acquisition Agreement signed by the Company on May 6, August 3, August 3, August 0, and October 0, 20 15.
1. According to the news of Qiqi APP, Shanghai Youkadi Biomedical Technology Co., Ltd. (referred to as Youkadi), which focuses on the research and development of CAR-T independent innovative products, recently announced the completion of tens of millions of rounds of B+ financing.
2. This round of financing was led by Deguan Capital, and Ryan followed suit. This round of financing will be used to promote the company's first CAR-T 2.0 product scart-19 injection clinical trial, the rapid start of several new product IND applications and clinical trials, and the development of new candidate products for solid tumor application. Verification.
3. According to the company's investigation, Youkadi was founded in February 2005. The company is a developer of cellular immunotherapy drugs, and is one of the earliest bio-high-tech enterprises in China to develop, transform and industrialize a new generation of immune cell gene therapy technologies and products.
4. Committed to the development and clinical application of cellular immunotherapy with chimeric antigen receptor T cell technology (CAR-T).